Black Friday is Now! Don’t miss out on up to 60% OFF InvestingProCLAIM SALE

Gold Futures Dip for 4th Day as Covid-19 Trial Drug Overwhelms Markets

Published 04/29/2020, 03:54 PM
Updated 04/29/2020, 05:02 PM
XAU/USD
-
GILD
-
GC
-

By Barani Krishnan 

Investing.com - Gold futures fell for a fourth-straight session on Wednesday as markets from Wall Street to oil rose on optimism for U.S. recovery from the Covid-19 pandemic after relatively successful clinical trials for a drug manufactured to treat those infected by the virus.

Both futures of the yellow metal and prices of physical bullion, however, held to their $1,700 an ounce perch, which has proven the support point of comfort for gold bugs, amid assurances that the road to economic normalcy in the United States was still some way off. 

Gold is a hedge against economic and political troubles and negative news tends to support its prices.

Gold futures for June delivery on New York’s COMEX settled down $8.80, or 0.5%, at $1,713.40 per ounce. 

Gilead (NASDAQ:GILD) said a Stage 1 trial of its retroviral drug called remdesivir had shown improved symptoms in coronavirus patients who were given the drug early. The effect on those who were given it at a later stage was, however, not as positive, Gilead said.  

But White House health advisor Anthony Fauci praised the progress in the remdesivir, saying it was “quite good news” and presented “clear-cut positive effect in diminishing time to recover”.  

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.